Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin

real-world data

  • Open Access
    Development and Validation of an EHR-based Algorithm for Identifying Pneumocystis jirovecii Pneumonia
    YU KITAMURA, MASAMI TSUCHIYA, HIROTOSHI IIHARA, SHUJI SAKURAI, JUNKI ENDO, KEISUKE KUMADA and YUKARI TSUBATA
    In Vivo May 2026, 40 (3) 1715-1721; DOI: https://doi.org/10.21873/invivo.14322
  • Open Access
    Onset and Outcomes of Immune-related Adverse Events in Genitourinary Cancer Treated With Immune Checkpoint Inhibitors
    MINORU KATO, SHOMA YAMAMOTO, TAISUKE MATSUE, NAO YUKIMATSU, TAIYO OTOSHI, TAKESHI YAMASAKI, HIROYASU KANEDA, MASAFUMI KURAJOH, ASAHIRO ITO, NAOSHI ODAGIRI, AKINOBU NAKATA, AIKO KOBAYASHI, KATSUYUKI KURATSUKURI and JUNJI UCHIDA
    In Vivo March 2026, 40 (2) 980-991; DOI: https://doi.org/10.21873/invivo.14254
  • Open Access
    Efficacy of Lenvatinib Therapy for Thyroid Cancer by Pathological Type: A Retrospective Real-world Study
    MIOKO MATSUO, MAMORU ITO, KENJI TSUCHIHASHI, HIROFUMI OHMURA, KAZUKI HASHIMOTO, RYUNOSUKE KOGO, MASANOBU SATO, SHOGO MASUDA and TAKASHI NAKAGAWA
    In Vivo September 2025, 39 (5) 2854-2861; DOI: https://doi.org/10.21873/invivo.14085
  • Open Access
    Risk of Pneumocystis jirovecii Pneumonia in Patients With HIV in Taiwan: Evidence from a Cross-sectional Study
    JIUN-YI WANG, KUANG-HUA HUANG, CHIH-JAAN TAI, SHUO-YAN GAU, TUNG-HAN TSAI, CHUN-NAN WU and CHIEN-YING LEE
    In Vivo March 2025, 39 (2) 1054-1066; DOI: https://doi.org/10.21873/invivo.13910
  • Open Access
    Prognostic Significance of Inflammation-based Scores in Pancreatic Cancer Patients Treated With Palliative Chemotherapy: A Single Institution Experience
    MARIÁN LIBERKO, TOMÁŠ SYCHRA, MARTIN OLIVERIUS and RENATA SOUMAROVÁ
    In Vivo November 2024, 38 (6) 2782-2794; DOI: https://doi.org/10.21873/invivo.13758
  • Open Access
    Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan
    TOMOMI MANAKO, RYUJI YASUMATSU, TAKAFUMI NAKANO, MIOKO MATSUO, TORANOSHIN TAKEUCHI, MASAHIKO TAURA, AKIHIRO TAMAE, MORIYASU YAMAUCHI, MUNEYUKI MASUDA, KENICHI TAGUCHI and TAKASHI NAKAGAWA
    In Vivo March 2023, 37 (2) 747-755; DOI: https://doi.org/10.21873/invivo.13137
  • You have access
    Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis
    TAKASHI SASAKI, RYO KANATA, IKUHIRO YAMADA, MASATO MATSUYAMA, MASATO OZAKA and NAOKI SASAHIRA
    In Vivo January 2019, 33 (1) 271-276; DOI: https://doi.org/10.21873/invivo.11471
In Vivo

© 2026 In Vivo

Powered by HighWire